References
- Leoncini L, Raphaël M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC, Lyon, France, 262–264 (2008).
- Magrath I. Towards curative therapy in Burkitt lymphoma: the role of early African studies in demonstrating the value of combination therapy and CNS prophylaxis. Adv. Hematol. 2012, 130680 (2012).
- Burkitt D. A sarcoma involving the jaws in African children. Br. J. Surg. 46(197), 218–223 (1958).
- Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br. J. Haematol. 156(6), 744–756 (2012).
- Sander S, Calado DP, Srinivasan L et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 22(2), 167–179 (2012).
- Hummel M, Bentink S, Berger H et al.; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354(23), 2419–2430 (2006).
- Dave SS, Fu K, Wright GW et al.; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N. Engl. J. Med. 354(23), 2431–2442 (2006).
- Richter J, Schlesner M, Hoffmann S et al.; ICGC MMML-Seq Project. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44(12), 1316–1320 (2012).
- Love C, Sun Z, Jima D et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44(12), 1321–1325 (2012).
- Schmitz R, Young RM, Ceribelli M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418), 116–120 (2012).
- Quong MW, Romanow WJ, Murre C. E protein function in lymphocyte development. Annu. Rev. Immunol. 20, 301–322 (2002).
- Seitz V, Butzhammer P, Hirsch B et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE 6(11), e26837 (2011).
- Soldini D, Montagna C, Schüffler P et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann. Oncol. 24(1), 193–201 (2013).
- Soldini D, Campo E. New insights into the diagnosis of lymphomas. Ann. Oncol. 23(Suppl. 10), 83–88 (2012).
- Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152(4), 714–726 (2013).
- Puente XS, López-Otín C. The evolutionary biography of chronic lymphocytic leukemia. Nat. Genet. 45(3), 229–231 (2013).
- Kirk R. Targeted therapies: new targets in Burkitt lymphoma? Nat. Rev. Clin. Oncol. 9(10), 551 (2012).
- Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10(3), 143–153 (2013).
- Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 12(3), 229–243 (2013).
- Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol. 137(10), 1409–1418 (2011).